"Aromatase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.
| Descriptor ID |
D047072
|
| MeSH Number(s) |
D27.505.519.389.870.300 D27.505.696.399.450.327.149 D27.505.696.399.450.855.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aromatase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Aromatase Inhibitors".
This graph shows the total number of publications written about "Aromatase Inhibitors" by people in this website by year, and whether "Aromatase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 4 | 0 | 4 |
| 2010 | 2 | 0 | 2 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aromatase Inhibitors" by people in Profiles.
-
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Breast Cancer Res. 2024 Jun 07; 26(1):95.
-
Assessment of Breast Cancer Management in Sub-Saharan Africa. JCO Glob Oncol. 2021 09; 7:1593-1601.
-
Efficacy of Non-Testosterone-Based Treatment in Hypogonadal Men: A Review. Sex Med Rev. 2021 07; 9(3):381-392.
-
Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
-
Breast reconstruction in the patient with stable, metastatic breast cancer. Breast J. 2020 02; 26(2):335-336.
-
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. Br J Cancer. 2019 01; 120(2):247-255.
-
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.
-
Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment. Am J Obstet Gynecol. 2018 04; 218(4):390-400.
-
Don't Be Fooled by DCIS. Oncology (Williston Park). 2017 07 15; 31(7):549-51, 560-1.
-
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122.